Agreement with Cellmid to Access Chinese Health Market
This contract is YPB's first with an Australian company driving advanced life sciences expertise into consumer markets and fits in its target verticals of pharmaceuticals, natural beauty, and health and wellness markets where YPB has other important clients.
Headquartered in Sydney, Cellmid has drug development programs in multiple disease indications. Through wholly owned subsidiary Advangen, it also has an exponentially growing consumer health business based around its novel FGF5 inhibitor hair growth products. Branded evolis(R), the products have demonstrated dramatic hair growth efficacy in blinded, placebo controlled clinical studies. Cellmid sells its hair growth products in Australia and Japan and is expanding distribution in other territories. It has recently secured ultra-premium retailer Neiman Marcus as its first retail partner in the USA and has been granted import permits and registrations for China. Cellmid's products are positioned to fit in the rapidly growing OTC (over-the-counter), non-prescription, natural medicines and cosmetics category.
YPB will supply Cellmid with QR labels to be applied to its products. In addition to protecting product authenticity, QR codes enable the company's packaging to become data collection and communication points. Mobile device scanning of the QR code launches a cascade of digital events that sees CONNECT capture and analyse data that gives Cellmid deep knowledge of its consumers and the capacity to develop personalised interactions with them. Once that connection is established, CONNECT can then be used for a broad range of personalised education, marketing and promotional activities to enrich consumer experience and increase brand loyalty. Marketing costs are expected to be reduced and brand value maximized over time as the relationship between Cellmid and its customers develops.
YPB Executive Chairman John Houston said: "We are pleased to help an exciting Australian success story with novel technology to connect with its customers wherever they may be in the world by employing our CONNECT platform. This relationship with Cellmid also demonstrates that YPB can help propel cross border e-commerce and international brand building by allowing brands to know and connect with consumers who would otherwise remain entirely anonymous. We expect a much greater involvement with Australian exporters, particularly those building their China presence, and we look forward to growing together with Cellmid over the coming three years and beyond."
"Access to the CONNECT platform is expected to be transformative for our consumer strategy in China" said Cellmid CEO Maria Halasz. "Knowing the customer behind each sale means that we can become partners in their hair health and provide tailored, personalised information and products to suit their individual needs. Together with our multilayered strategy to access the Chinese consumer market, the CONNECT platform is expected to improve our return on marketing investment significantly."
Cellmid (ASX:CDY) is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel target midkine (MK). Intellectual property pertaining to MK is being exploited through wholly owned subsidiaries Lyramid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia, the USA and Japan, and currently broadening distribution in other territories. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.
Advangen Limited - Cellmid's Consumer Health Division
In 2013 Cellmid acquired Advangen Inc. (Japan), the owner of a range of FGF5 inhibitor hair growth technologies and became the first, and still the only, company globally with an FGF5 inhibitor hair growth product range on the market. Cellmid has continued innovation and product development and filed a number of new patent applications covering several hair growth agents including midkine and a group of novel FGF5 inhibitors. In addition to distribution in Australia, The USA and Japan the Company is actively expanding into other markets including Asia and Europe.
About YPB Group Ltd
YPB Group Ltd (ASX:YPB) brings packaging to life through its proprietary technology suite that provides certainty of authenticity and connects brands directly to consumers enabling new levels of market intelligence and ROI data capture.
In an evolving marketplace and with the rapid growth of cross border commerce, our expertise presently focuses on the rapidly growing consumer markets of Australia, South East Asia and China.
YPB Group Ltd